|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Drug regimens applied in the year before index hospitalization were as follows: no IBD drugs (43.6% ulcerative colitis, 43.1% Crohn's disease); 5-ASA (45.7% ulcerative colitis, 19.1% Crohn's disease); local steroids (17.9% ulcerative colitis, 17.6% Crohn's disease); systemic steroids (38.6% ulcerative colitis, 29.4% Crohn's disease); immunomodulators (10.7% ulcerative colitis, 18.1% Crohn's disease); biologics (10% ulcerative colitis, 24% Crohn's disease); and calcineurin inhibitors (2.1% ulcerative colitis, 1.5% Crohn's disease).
|
31834046 |
2020 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with PSC-IBD were more likely to be treated with only 5-ASA, compared with controls (odds ratio [OR], 3.04; 95% CI, 1.44-6.41) and to have IBD in clinical remission (OR, 2.94; 95% CI, 1.78-4.87).
|
31493578 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The incidence of immune-mediated diseases in IBD patients was higher than that of non-IBD population.5-ASA use may reduce this risk.
|
30506945 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Additional biological testing applied the assay to samples collected from healthy control participants and two groups diagnosed with inflammatory bowel disease (IBD) (one group treated with the anti-inflammatory 5-aminosalicylic acid (5-ASA) and one group untreated), with results showing significant differences in the concentrations of picolinic acid, kynurenine, and xanthurenic acid.
|
30848589 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
5-ASA is a therapeutic drug to cure mild to moderate inflammatory bowel disease.
|
31310787 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC.
|
31013494 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the use of topical and systemic 5-ASA therapy in children and adolescents with inflammatory bowel disease.
|
28644308 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Abbreviations: ADA: Adalimumab; CD: Crohn disease; ECCO: European Crohn's and Colitis Organisation; EEN: exclusive enteral nutrition; ESPGHAN: European Society for Paediatric Gastroenterology Hepatology and Nutrition; FMT: faecal microbiota transplantation; GDP: gross domestic product; HIC: high-income countries; IBD: inflammatory bowel disease; IBDU: inflammatory bowel disease unclassified; IC: ileocolonoscopy; IFX: infliximab; IPAA: ileal pouch anal anastomosis; LMIC: low- and middle-income countries; MH: mucosal healing; OGD: oesophago-gastroduodenoscopy; PCDAI: Paediatric Crohn's Disease Activity Index; PIBD: paediatric inflammatory bowel disease; PUCAI: Paediatric Ulcerative Colitis Activity Index; UC: ulcerative colitis; UGIT: upper gastrointestinal tract; VEO-IBD: very early-onset IBD; WLE: white light endoscopy; 5-ASA: 5 aminosalicylic acid; 6-MP: 6-mercaptopurine.
|
30900526 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated IBD patient outcomes after continuation/discontinuation of 5-ASA when biologics were administered as maintenance treatment.
|
31471699 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Groups were formed: 'possible PD' group, including all who received an anti-Parkinson agent; 'possible IBD' group, those treated with mesalazine and/or derivatives (5-aminosalicylic acid (5-ASA)); and 'possible PD and IBD', including those receiving both anti-Parkinson agent and 5-ASA.
|
31221869 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, spot (Nac-)5-ASA urinalysis is not applicable to assess 5-ASA adherence in daily IBD care.
|
29073323 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results reveal a multifaceted and previously unrecognized effect of 5-ASA on the growth and virulence of IBD- and CRC-associated E. coli, in addition to its inhibitory effect on host cell inflammatory responses.
|
30050110 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This contrasts a small decrease in immunomodulator and 5-ASA use for CD and relative constancy of other classes including corticosteroids-only use as primary IBD medication from 2007 to 2015.
|
29164650 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
5-ASA usage is associated with decreased risks of hospitalization and operation for patients with IBD, whereas thiopurine, corticosteroids, and anti-TNF-α agents are associated with increased risks of hospitalization and hepatitis B and TB reactivation.
|
30373275 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Mesalazine (5-ASA), a drug largely used in inflammatory bowel disease, has potent antinflammatory and antioxidant effects.
|
29030981 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
5-ASA agents were used more commonly in the pediatric IBD population (96.9% vs. 79.9%; p = 0.0034) as compared to adults whereas corticosteroids (87.5% vs. 76.9%; p = 0.28) and infliximab (25% vs. 9.2%; p = 0.054) were used more frequently in the pediatric CD subgroup as compared to adult CD subgroup.
|
29572605 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In study 2, we compared the incidence of herpes zoster among patients with IBD treated with only 5-ASA, with thiopurines, with antagonists of tumor necrosis factor (TNF), with a combination of thiopurines and TNF antagonists, and with vedolizumab.
|
29309905 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, zinc ion cross-linked alginate/N-succinyl-chitosan blend MS appeared to be a good candidate for co-delivery of zinc and 5-ASA to colon, and had great potential application in inflammatory bowel diseases (IBD) treatment.
|
27851980 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The TB IRs among IBD patients prescribed 5-ASA, corticosteroids, immunomodulators and anti-TNF-α were 143.5, 208.5, 284.6 and 554.1 per 100 000 person-years, respectively.
|
27933686 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
No medication seemed to affect vascular measurements, though stiffness parameters were significantly higher in patients treated with 5-ASA (11.9 (9.7) vs 18.2 (10.2), P<0.021), suggesting a lack of efficacy of 5-ASA in protecting IBD patients from early atherogenesis.
|
27773555 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Mesalazine (5-aminosalicylic acid, 5-ASA), a currently used drug for anti-inflammatory bowel disease, is easily oxidized by HOCl, a strong oxidant generated in gut inflammation, to produce electrophilic quinones.
|
28473247 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to examine the effects of AZA, MP, and 5-ASA on the growth of IBD-associated bacterial species and to identify bacterial enzymes involved in immunosuppressive drug metabolism.
|
28424670 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Drugs such as mesalamine (5-ASA) are currently recommended for the treatment of inflammatory bowel disease (IBD).
|
28556814 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
5-ASA showed a chemopreventive effect against CRC/Dys in IBD patients (OR = 0.58, 95% CI: 0.45-0.75).
|
27906680 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thiopurines are increasingly used in the treatment of inflammatory bowel disease (IBD), being the most common immunosuppressive therapy; however, potentially harmful interactions between thiopurines and other drugs (especially 5-aminosalicylic acid, 5-ASA) were described.
|
19650826 |
2009 |